ArticlePsychopharmacology2016
Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.
Article in Psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Serotonin 5-HTACS chemical neuroscience · 2025Article
- Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.Journal of psychopharmacology (Oxford, England) · 2022Review
- The Effects of Drug Treatments for ADHD in Measures of Cognitive Performance.Current topics in behavioral neurosciences · 2022Article
- A role for reward valuation in the serotonergic modulation of impulsivity.Psychopharmacology · 2021Article
- Selective serotonin receptor stimulation of the ventral tegmentum differentially affects appetitive motivation for sugar on a progressive ratio schedule of reinforcement.Behavioural brain research · 2021Article
- Role of serotonin in body weight, insulin secretion and glycaemic control.Journal of neuroendocrinology · 2021Review
- Chronic Lorcaserin Treatment Reverses the Nicotine Withdrawal-Induced Disruptions to Behavior and Maturation in Developing Neurons in the Hippocampus of Rats.International journal of molecular sciences · 2021Article
- Safety and Preliminary Efficacy of Lorcaserin for Cocaine Use Disorder: A Phase I Randomized Clinical Trial.Frontiers in psychiatry · 2021Article
- Serotonin in Animal Cognition and Behavior.International journal of molecular sciences · 2020Review
- Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain.Frontiers in pharmacology · 2020Article
- Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.Pharmacology, biochemistry, and behavior · 2018Review
- Choice between delayed food and immediate opioids in rats: treatment effects and individual differences.Psychopharmacology · 2017Article
- Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis.Journal of cellular physiology · 2017Review
- Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive-Compulsive Disorder.Frontiers in psychiatry · 2017Article
- Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience.BMC obesity · 2017Article
- Serotonin receptors in depression: from A to B.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe 5-HT2C receptor agonist lorcaserin (Belviq®) has been approved by the FDA for the treatment of obesity. Impulsivity is a contributory feature of some eating disorders.
objectiveExperiments investigated the effect of lorcaserin and the highly selective 5-HT2C agonist CP-809101 on measures of impulsivity and on reinstatement of food-seeking behaviour, a model of dietary relapse. The effect of both drugs on 22-h deprivation-induced feeding was also examined, as was the effect of prefeeding in each impulsivity test.
resultsLorcaserin (0.3-0.6 mg/kg SC) and CP-809101 (0.6-1 mg/kg SC) reduced premature responding in rats trained on the 5-CSRTT and improved accuracy in a Go-NoGo task by reducing false alarms. At equivalent doses, both drugs also reduced reinstatement for food-seeking behaviour. Neither drug altered impulsive choice measured in a delay-discounting task. Lorcaserin (1-3 mg/kg SC) and CP-809101 (3-6 mg/kg SC) reduced deprivation-induced feeding but only at higher doses.
conclusionsThese results suggest that in addition to previously reported effects on satiety and reward, altered impulse control may represent a contributory factor to the anti-obesity property of 5-HT2C receptor agonists. Lorcaserin may promote weight loss by improving adherence to dietary regimens in individuals otherwise prone to relapse and may be beneficial in cases where obesity is associated with eating disorders tied to impulsive traits, such as binge eating disorder.
Indexed as
Identifiers
27241709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.